Moderna Aktie News

CNBC's Jim Cramer said Moderna has evolved beyond its Covid-era business, arguing the biotech company's expanding pipeline in treatments for cancer and other diseases provides a compelling long-term investment thesis. While Cramer cautioned that many of Moderna's most promising programs remain years from commercialization, he said he would look to buy into weakness.

All of these stocks have soared by triple digits during the first half of 2026.

Moderna Inc. (MRNA) shares surged nearly 10% on Friday, extending a powerful rally that has lifted the stock about 40% over the past month and significantly outperformed the broader market. The gains followed the company's Science Day presentation and investor event, where Moderna outlined an ambitious strategy to expand beyond its COVID-19 vaccine business and build a diversified portfolio spa...

Shares of AbbVie, Eli Lilly and Johnson & Johnson were on track to hit all-time highs Friday, in the latest signal that investor appetite for the biopharmaceutical sector is back.

Moderna shares pace toward their highest close since late 2024 after unveiling a new cell therapy program.

Provides broad overview of Company's research and early development programs expected to continue to fuel future growth Highlights validation of T-cell engager modality with mRNA-2808 in multiple myeloma, supporting rapid advancement of second T-cell engager mRNA-2151 in ovarian cancer Introduces in vivo CAR-T modality with mRNA-6007 moving into early development for autoimmune diseases CAMBRID...

Moderna, Inc. is transitioning from Covid-era reliance to a diversified mRNA pipeline, with a cautious buy rating and a suggested entry below $50. MRNA's mFlusiva flu vaccine highlights benefits of mRNA vaccines (speed, flexibility, manufacturing efficiency), showing superior efficacy to incumbents, with FDA approval expected soon and blockbuster potential driving 2027+ revenue ramp. Pipeline c...

Moderna said the FDA's Vaccines and Related Biological Products Advisory Committee voted unanimously that the benefits of the vaccine, mRNA-1010, exceed the risks for the prevention of flu in adults 50 through 64 years old, and in adults 65 years of age and older.